Publication | Closed Access
Phase I Clinical and Pharmacologic Study of Chronic Oral Administration of the Farnesyl Protein Transferase Inhibitor R115777 in Advanced Cancer
130
Citations
17
References
2002
Year
Continuous dosing of R115777 is feasible with an acceptable toxicity profile at a dose of 300 mg bid.
| Year | Citations | |
|---|---|---|
Page 1
Page 1